Advances in Treatment of Transfusion-dependent Lower-risk Myelodysplastic Syndromes
At present, the patients with transfusion-dependent lower-risk myelodysplastic syndromes (MDS) have limited treatment options when erythropoiesis-stimulating agent is ineffective or relapsed. With more understanding of the pathological and molecular genetics characteristics of MDS, the development o...
| 出版年: | Zhongliu Fangzhi Yanjiu |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | 論文 |
| 言語: | 中国語 |
| 出版事項: |
Magazine House of Cancer Research on Prevention and Treatment
2021-04-01
|
| 主題: | |
| オンライン･アクセス: | http://html.rhhz.net/ZLFZYJ/html/8578.2021.20.1020.htm |